DNTH

Dianthus Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 4/10
  • Value↓ 0/10
Dianthus Therapeutics sales and earnings growth
DNTH Growth
Neutral
  • Revenue Y/Y↓ -67.35%
  • EPS Y/Y↓ -64.71%
  • FCF Y/Y↓ -65.13%
Dianthus Therapeutics gross and profit margin trends
DNTH Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -7973.30%
  • ROIC 5Y↓ -84.46%
Dianthus Therapeutics net debt vs free cash flow
DNTH Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Dianthus Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗